CasNo.357336-20-0,brivaracetam,(357336-20-0) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99% purity
Payment Terms : T/T,,MoneyGram,Other

Keywords

brivaracetam 357336-20-0 99% purity

Quick Details

Appearance:powder
Application:intermediate
PackAge:According to the need of packing
ProductionCapacity:100|Metric Ton|Month
Storage:Sealed in dry,Room Temperature
Transportation:air,sea,courier

Superiority:

Product Name:   brivaracetam
Synonyms:   (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;API-Anti Epilepsy;brivaracetam
CAS:   357336-20-0
MF:   C11H20N2O2
MW:   212.29
EINECS:   801-184-2
Product Categories:   API;APIs;Brain health drug;Nootropic
Mol File:   357336-20-0.mol

Details:

Melting point    76.38°
alpha    D25 -60.57° (c = 1 in methanol)
Boiling point    409.3±28.0 °C(Predicted)
density    1.062
pka   15.74±0.50(Predicted)c

Description   Brivaracetam, a chemical analog of Levetiracetam, is a racetam derivative with anticonvulsant effect. It is used for the treatment of partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs. The exact mechanism of brivaracetam's anti-epileptogenic activity is unknown. What is known is thatbrivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam can also inhibit Na+ channels which may also contribute to its anti-epileptogenic action.
Overview and History   Brivaracetam is an orally bioavailable levetiracetam derivative, with anticonvulsant activity. It can be used in the treatment of partial-onset seizures[1-3]. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. It was approved by the federal drug administration of USA[FDA] on Feb 19th 2016[1-3].
Application   Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older[4,5]. It provides a new monotherapy treatment option for epilepsy patients 16 years of age and older who suffering partial-onset[focal] seizures, which can be initiated at a therapeutic dose at day one[5].
Mode of action   The accurate mode of action of brivaracetam remains unclear. It is known that Brivaracetam can strongly bind to SV2A[6-8], which is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A[6-8]. It may access the luminal side of recycling synaptic vesicles during vesicular endocytosis, which may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action[9].